CD44 and neoplasm: Juglone meaningfully suppressed the growth of both CD44+CD133+ tumor-initiating Caco-2 cells and ΔCD44+CD133+ non-tumor-initiating Caco-2 cells in a concentration-dependent manner (Figure 5G).